Explore more price target data and ratings for Guardant Health, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Guardant Health, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This in…
Q2 2026 saw 44% revenue growth to $335M, driven by strong oncology, biopharma, and screening performance. Major milestones included FDA approvals, Shield's inclusion in ACS guidelines, and UnitedHealth coverage, expanding access to 70M lives. Full-year guidance was raised on robust demand and opera…
Q2 revenue grew 44% year-over-year to $335 million, driven by strong oncology, biopharma, and screening performance. FDA approvals, ACS guideline inclusion, and UnitedHealth coverage expanded Shield's reach to 70 million lives. Raised 2026 revenue guidance and accelerated investments in lab capacit…
Guardant Health, Inc. reported results for the quarter ended 2026 with revenue of $334.98M, up 44.3% from $232.09M a year earlier, while the company recorded a net loss of ($120.14M) and diluted loss per share of ($0.9).Financial Highlights¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Report…
Revenue grew 44% year-over-year to $335.0 million in Q2 2026, driven by strong oncology and screening test volume growth, while net loss widened to $120.1 million due to increased R&D and commercial investments. Cash reserves remain robust at $1.2 billion, supporting ongoing expansion and innovatio…
Q2 2026 saw 44% revenue growth to $335M, led by Oncology and a 257% surge in Screening revenue. Full-year guidance was raised, with Shield adoption accelerating due to new coverage and FDA approvals, and cash reserves remain strong at $1.2B.Original document: Guardant Health, Inc. [GH] Slides Relea…
Diagnostics company Guardant Health NASDAQ:GHwill be announcing earnings results this Thursday after market close. Here’s what to look for.Guardant Health beat analysts’ revenue expectations last quarter, reporting revenues of $301.7 million, up 48.3% year on year. It was an exceptional quarter for…
Explore more price target data and ratings for Guardant Health, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Guardant Health, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This in…
(16:24 GMT) Guardant Health Price Target Raised to $200.00/Share From $160.00 by Evercore ISI Group
Explore more price target data and ratings for Guardant Health, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Guardant Health, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This in…
(11:04 GMT) Guardant Health Price Target Raised to $190.00/Share From $135.00 by B of A Securities
